C. diff Risk


Oral Bioavailability


Approximate Cost



1.5 - 3 g IV q6-8h

Higher doses may be used for infections due to MDR Acinetobacter spp.

General Information

Acceptable Uses

Treatment of:

  • human or animal bites if parenteral therapy is needed

  • oral infections

  • lung abscess

  • culture-negative endocarditis (ID consult advised)

  • multi-drug resistant (MDR) Acinetobacter spp. (ID consult advised)

Unacceptable Uses

  • Empiric treatment of biliary tract infections, diverticulitis, or secondary/peritonitis/GI perforation.

  • Use should be limited to infections that are proven to be susceptible.